SCHEMBL10174980

SCHEMBL10174980

CCOc1cc(I)cc(NC(=O)NCC(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.54
KMT2A Q03164 6/20 0.54
LMNA P02545 3/20 0.54
PAX8 Q06710 3/20 0.54
FGFR3 P22607 5/20 0.44
KDR P35968 4/20 0.44
MAPT P10636 6/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
HTT P42858 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
S1PR2 O95136 1/20 0.43
S1PR4 O95977 1/20 0.43
GAA P10253 1/20 0.43
XBP1 P17861 1/20 0.43
S1PR3 Q99500 1/20 0.43
S1PR5 Q9H228 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
MITF O75030 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10174972 0.87 FGFR3 (0.44) MEN1KMT2ALMNAFGFR3KDR
SCHEMBL11929166 0.78 L3MBTL1 (0.47) MEN1KMT2ALMNAFGFR3KDR
SCHEMBL10174976 0.78 L3MBTL1 (0.47) LMNAFGFR3KDRSMN1; SMN2HTT
SCHEMBL10174975 0.77 MEN1 (0.47) MEN1KMT2ALMNAPAX8FGFR3
SCHEMBL10174933 0.68 FGFR4 (0.46) MEN1KMT2ALMNAPAX8FGFR3
SCHEMBL10225528 0.68 NOTUM (0.52) MEN1KMT2ALMNAFGFR3KDR
SCHEMBL20725429 0.66 RAB9A (0.55) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL13363823 0.66 L3MBTL1 (0.49) MEN1KMT2ALMNAFGFR3KDR
SCHEMBL16920271 0.65 NPC1 (0.60) MEN1KMT2AMAPTSMN1; SMN2HTT
SCHEMBL10224429 0.65 L3MBTL1 (0.45) MEN1KMT2ALMNAFGFR3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722687-B2 Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy ASTEX THERAPEUTICS LTD (GB) 2014-05-13 US disclosed
US-8722687-B2 Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy ASTEX THERAPEUTICS LTD (GB) 2014-05-13 US disclosed
US-20120041000-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY ASTEX THERAPEUTICS LIMITED (GB) 2012-02-16 US disclosed
US-20120041000-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY ASTEX THERAPEUTICS LIMITED (GB) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041000-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY FGFR1, FGFR3, FGFR2 MEN1 2623/4885KMT2A 1043/4885LMNA 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.